Oltmans Curtis Gale, Chief Legal Officer at Fulcrum Therapeutics ($FULC), made one open market sale of company shares in the last year, totaling about $45,000. His most recent sale occurred on December 15, 2025. This places him 10,509th among 11,678 insiders by sale value, well below the average of $8.6 million across about 6.4 transactions per insider. He reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Fulcrum Therapeutics, Inc. | $FULC | Oltmans Curtis Gale | Chief Legal Officer | A | Stock Option (right to buy) | 170000 | $0.00 | 170,000.0000 | 62,597,000 | 9999.99% | 0.27% |
| Dec. 15, 2025 | Fulcrum Therapeutics, Inc. | $FULC | Oltmans Curtis Gale | Chief Legal Officer | S | Common Stock | 3452 | $12.92 | 10,252.0000 | 62,597,000 | 25.19% | 0.01% |
| Jan. 24, 2025 | Fulcrum Therapeutics, Inc. | $FULC | Oltmans Curtis Gale | Chief Legal Officer | A | Stock Option (right to buy) | 225000 | $0.00 | 225,000.0000 | 61,984 | 9999.99% | 100.00% |
| Sept. 23, 2024 | AVENUE THERAPEUTICS, INC. | $ATXI | Oltmans Curtis Gale | Director | A | Employee stock option (right to buy) | 30000 | $0.00 | 30,000.0000 | 341,324 | 9999.99% | 8.79% |
| Jan. 26, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Oltmans Curtis Gale | Chief Legal Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 61,310 | 9999.99% | 100.00% |
| June 30, 2023 | AVENUE THERAPEUTICS, INC. | $ATXI | Oltmans Curtis Gale | Director | A | Employee stock option (right to buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |